Fig. 1 · Structure

Documents & Downloads

AZD8055

Cat. No. A10114 CAS 1009298-09-2

mTOR Inhibitor

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.

In Stock

Publications for AZD8055

5 publications citing this product

  1. Junya Takegaki, .et al. , Sci Rep, 2025, Nov 19;15(1):40805 PMID: 41257941
  2. Zhen-Ye Lv, .et al. , Ann Clin Lab Sci, 2022, Nov;52(6):947-955 PMID: 36564063
  3. L. M. C. Koene, .et al. , ACTN, 2019, June PMID: 31353861
  4. Helga Weber, .et al. , Oncotarget, 2015, Oct 13; 6(31): 31877-31888 PMID: 26397134
  5. Kentaro Hirose, .et al. , BMC Dev Biol, 2014, 14: 42. PMID: 25480380

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AZD8055 suppresses mTORC1 and mTORC2 signaling in breast cancer cells, reducing phosphorylation of p70S6K, 4E-BP1 and AKT Ser473. Suppression of AKT Ser473 does not necessarily mean sustained inhibition of AKT activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
mTOR(truncated) IC50 0.13nM
mTOR(fulllength) IC50 0.8nM
DNA-PK IC50 1370nM
PI3Kδ IC50 3200nM
PI3Kα IC50 3590nM
ATM IC50 7350nM
PI3Kγ IC50 >14790nM
PI3Kβ IC50 18900nM

8 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 0.12 μM Antiproliferative activity against human A375 cells after 72 hrs by SRB assay [PMID: 28235701]
A549 IC50 0.05 μM Antiproliferative activity against human A549 cells after 72 hrs by SRB assay [PMID: 28235701]
HEK293 IC50 1.4 μM Antiproliferative activity against HEK293 cells after 72 hrs by SRB assay [PMID: 28235701]
MCF7 IC50 0.14 μM Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay [PMID: 28235701]
MCF7 IC50 27 nM Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay [PMID: 29945756]
MDA-MB-468 IC50 0.024 μM Inhibition of mTORC2 in human MDA-MB-468 cells assessed as reduction of AKT phosphorylation at Ser473 after 2 hrs [PMID: 23375793]
MDA-MB-468 IC50 0.027 μM Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction of pS6 phosphorylation at Ser235/236 after 2 hrs [PMID: 23375793]
NCI-H460 IC50 0.01 μM Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay [PMID: 28235701]
PC-3 IC50 36.7 nM Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay [PMID: 29945756]
SK-OV-3 IC50 55 nM Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay [PMID: 29945756]
U-87MG ATCC IC50 0.19 μM Antiproliferative activity against human U87 cells after 72 hrs by SRB assay [PMID: 28235701]
U-87MG ATCC IC50 21.2 nM Antiproliferative activity against human U87MG cells assessed as reduction in cell viability after 48 hrs by CCK8 assay [PMID: 29945756]

12 records · Scroll to view more

In Vitro Studies

In BT-474 cells exposed to 500 nM AZD8055, AKT activity fell to 15% of baseline at 8 h and recovered to 60% at 24 h. BT-474 and MDA-MB-468 cells also showed recovery of AKT Thr308 and substrate phosphorylation despite continued Ser473 suppression. [1]

mTOR pathway inhibition and time-dependent AKT rebound in breast cancer cells

Cell-based study · MCF-7, BT-474 and MDA-MB-468 human breast cancer cells; AKT activity time course in BT-474 cells. [1]

AZD8055 reduced phosphorylation of mTORC1 substrates and AKT Ser473. In BT-474 and MDA-MB-468 cells, AKT Thr308 and downstream substrate phosphorylation recovered despite persistent Ser473 suppression. This limits the use of Ser473 alone as a measure of sustained AKT inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p70S6K Thr389, S6 Ser240/244, 4E-BP1 and AKT Ser473 phosphorylationQualitative immunoblot response Suppression of mTORC1/2 signaling; 4E-BP1 suppression required more drug/time than p70S6K suppression.[1]
AKT Thr308 and AKT-substrate phosphorylationTime-dependent response Rebound began at 4 h; phosphorylation reached pretreatment levels at 8–16 h while AKT Ser473 remained inhibited.[1]
AKT kinase activity in immunoprecipitates from treated BT-474 cellsActivity relative to baseline 15% of baseline at 8 h; 60% at 24 h[1]

Literature-Reported Treatment Conditions

Treatment concentration
AZD8055: 0, 10, 20, 100, 200 and 500 nM for concentration response; 500 nM for time courses.
Exposure duration
4 h concentration response; time courses through 24 h.
Method
Cell exposure followed by immunoblotting or AKT activity measurement in cell-derived immunoprecipitates.
Co-treatment
No combination adopted. Rapamycin was a separate comparator in Figure 1A.
Reported limits
AZD8055-specific vehicle, replicate count and complete AKT assay supplement were not established from the inspected main text. Concentrations are experimental conditions, not recommendations.
Methods and source locations

Compound reported in the paper: AZD8055; Compound label in the paper: AZD8055

Results apply to the reported research material and model; no batch equivalence or product validation is asserted.

Figures 1A–B and 2A–C; corresponding Results; Cell culture and reagents; Immunoblot analysis; In vitro AKT kinase assay

p70S6K Thr389, S6 Ser240/244, 4E-BP1 and AKT Ser473 phosphorylation: Immunoblotting with actin loading controls and untreated lanes; comparison with rapamycin. — Figure 1A–B and caption; first Results subsection; Immunoblot analysis

AKT Thr308 and AKT-substrate phosphorylation: Immunoblot time course, with untreated baseline and actin controls; no band intensities estimated. — Figure 2A–B, panel 1; Results paragraphs on transient AKT inhibition

AKT kinase activity in immunoprecipitates from treated BT-474 cells: Cell Signaling AKT kinase assay; densitometry. Values stated in Results; Figure 2C error bars are standard error; n not specified in the inspected text/caption. — Figure 2C and caption; Results paragraph beginning To confirm; In vitro AKT kinase assay

In Vivo Studies

In U87-MG xenografts, the study reported 65% tumour growth inhibition with 20 mg/kg AZD8055 intraperitoneally and 85% orally. The intraperitoneal route produced a higher peak but shorter exposure and more transient pAkt suppression. These findings distinguish peak exposure, pharmacodynamic duration and tumour response. [2]

In a conditional Tsc1 epilepsy mouse model, AZD8055 at 15 mg/kg intraperitoneally each day did not significantly improve seizure onset, survival or average seizure frequency. Brain pS6 decreased in a separate cohort, whereas the reduction in pAKT was not statistically significant. [3]

Brain pathway modulation without seizure or survival benefit in a Tsc1 epilepsy model

Animal study · Tsc1 conditional deletion in CAMK2A-expressing neurons; male and female mice, 12–20 weeks old at induction. [3]

Daily AZD8055 produced a brain pS6 response but did not significantly improve the measured epileptic phenotype. Reduced pAKT was not statistically significant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Seizure onset, survival and average seizure frequencyTreatment effect No significant improvement in seizure onset, survival or average seizure frequency.[3]
Cortical and hippocampal pS6 Ser240/244 and pAKT Ser473Pharmacodynamic response pS6 significantly reduced in both regions; pAKT reduction was not statistically significant.[3]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily
Treatment course
Started 4 days after initiation of gene deletion. Independent PD cohort sampled on day 12, 2 h after the last dose.
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AZD8055
15 mg/kg
Vehicle-treated Tsc1-Cre+ mice; Cre− reference group for tissue biomarkers.No significant improvement in seizure onset, survival or frequency despite reduced cortical and hippocampal pS6. pAKT reduction was nonsignificant.[3]
AZD8055
Model: Tsc1 conditional deletion in CAMK2A-expressing neurons; male and female mice, 12–20 weeks old at induction.
Reported limits: Individual last treatment dates for the efficacy cohort are not specified in the inspected AZD8055 section; follow-up depends on survival. No brain drug concentration was measured in this adopted experiment.
Methods and source locations

Compound reported in the paper: AZD8055; Compound label in the paper: AZD8055 (Adooq Bioscience, A10114)

Results apply to the reported research material and model; no batch equivalence or product validation is asserted.

Methods: Animals and drug treatment; Figure 8A–C,E–F and caption; AZD8055/PF4708671 Results and Discussion

Seizure onset, survival and average seizure frequency: EEG and survival monitoring; onset/survival log-rank analysis; frequency one-way ANOVA with Dunnett post hoc test. AZD8055 n=6; vehicle n=25 for onset, n=19 for survival and n=13 for frequency. — Figure 8A–C and caption; Results AZD8055/PF4708671 subsection

Cortical and hippocampal pS6 Ser240/244 and pAKT Ser473: Immunoblotting in an independent cohort on day 12, 2 h after the last injection. pS6: AZD8055 n=4, vehicle n=3, Cre− n=3; pAKT: n=3 per group. Means with SEM; ANOVA/Dunnett. — Figure 8E–F and caption; corresponding Results

AZD8055 · Methods: Animals and drug treatment; Figure 8A–C,E–F and caption; corresponding Results

Route-dependent exposure, biomarker duration and xenograft growth inhibition

Animal study · U87-MG xenografts in female nu/nu:Alpk mice, 8–12 weeks old. [2]

At 20 mg/kg, intraperitoneal administration produced a higher peak but shorter exposure and less tumour growth inhibition than oral administration. The study links exposure duration to tumour pathway modulation; modeled parameters are not presented as direct measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
U87-MG xenograft tumour growth inhibitionTGI 65% after 20 mg·kg−1 i.p.; 85% after 20 mg·kg−1 orally.[2]
Exposure duration and tumour pAkt after 20 mg·kg−1 i.p.PK/PD time course Higher Cmax but shorter exposure than the same oral dose; pAkt decreased to 9.5% of basal level at 30 min and recovered to baseline by 16 h.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
20 mg/kg ip
20 mg·kg−1
Route-matched vehicle control shown in Figure 4C.Reported TGI 65%; transient pAkt suppression.[2]
20 mg/kg oral
20 mg·kg−1
Route-matched vehicle control shown in Figure 4C.Reported TGI 85%.[2]
20 mg/kg ip
Model: U87-MG xenografts in female nu/nu:Alpk mice, 8–12 weeks old.
Route: Intraperitoneal injection
Vehicle: Water for injection
Reported limits: Exact arm-specific n and efficacy course not specified in the inspected Figure 4 text/caption. Repeated i.p. dosing frequency not explicitly verified.
20 mg/kg oral
Model: U87-MG xenografts in female nu/nu:Alpk mice, 8–12 weeks old.
Route: Oral gavage
Frequency: Daily
Vehicle: 30% (w/v) Captisol, pH 5.0
Reported limits: Exact arm-specific n and efficacy course not specified in the inspected Figure 4 text/caption.
Methods and source locations

Compound reported in the paper: AZD8055; Compound label in the paper: AZD8055

Results apply to the reported research material and model; no batch equivalence or product validation is asserted.

Materials; animal and Pharmacokinetic/pharmacodynamic studies methods; route-comparison Results; Figure 4A–C and caption

U87-MG xenograft tumour growth inhibition: Observed efficacy values reported in Results; caliper tumour volumes compared with route-matched vehicle controls. No statistical significance inferred from these percentages. — Results: The antitumour efficacy of AZD8055 is only partly driven by high Cmax; Figure 4C; animal methods

Exposure duration and tumour pAkt after 20 mg·kg−1 i.p.: Plasma HPLC/MS and tumour phosphoprotein analysis. pAkt values come from Results, not estimates from plotted points. — Results: The antitumour efficacy of AZD8055 is only partly driven by high Cmax; Figure 4A–B; Pharmacokinetic/pharmacodynamic studies

20 mg/kg ip · Materials; animal methods; Figure 4A–C and caption; route-comparison Results; high-dose Results last sentence for 20 mg/kg oral daily schedule

20 mg/kg oral · Materials; animal methods; Figure 4A–C and caption; route-comparison Results; high-dose Results last sentence for 20 mg/kg oral daily schedule

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1009298-09-2
Applications mTOR Inhibitor
Formula C25H31N5O4
Molecular Weight 465.5
SMILES
C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 49 mg/mL (105.25 mM)
Water Insoluble
Ethanol 3 mg/mL (6.44 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
4% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery (2011). PMID: 22140653 DOI: 10.1158/2159-8290.cd-11-0085 Source material
  2. [2] Yates JWT, Holt SV, Logie A, et al. A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055. British journal of pharmacology (2017). PMID: 28556895 DOI: 10.1111/bph.13886 Source material
  3. [3] Koene LMC, van Grondelle SE, Proietti Onori M, et al. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model. Annals of clinical and translational neurology (2019). PMID: 31353861 DOI: 10.1002/acn3.50829 Source material

Publications

5 publications citing this product

  1. Junya Takegaki, .et al. , Sci Rep, 2025, Nov 19;15(1):40805 PMID: 41257941
  2. Zhen-Ye Lv, .et al. , Ann Clin Lab Sci, 2022, Nov;52(6):947-955 PMID: 36564063
  3. L. M. C. Koene, .et al. , ACTN, 2019, June PMID: 31353861
  4. Helga Weber, .et al. , Oncotarget, 2015, Oct 13; 6(31): 31877-31888 PMID: 26397134
  5. Kentaro Hirose, .et al. , BMC Dev Biol, 2014, 14: 42. PMID: 25480380

Added to your cart

View Cart Checkout
Loading...